CABALETTA BIO INC (CABA)
Health Care · CAR T cell therapy for autoimmune diseases · NASDAQ
Cabaletta Bio is developing engineered T cell therapies designed to reset the immune system through deep B cell depletion for autoimmune diseases with single-dose administration.
What CABALETTA BIO INC does
Cabaletta Bio is a late clinical-stage biotechnology company developing innovative engineered T cell therapies targeting autoimmune diseases. The company's proprietary CABA platform focuses on the CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) approach, which is designed to reset the immune system through transient and deep B cell depletion. The lead product candidate, resecabtagene autoleucel (rese-cel), is a fully human CD19-CAR T construct being evaluated in multiple Phase 1/2 trials and a registrational trial across multiple autoimmune indications including myositis, systemic lupus erythematosus, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
Themes: ["CAR T cell therapy"]
Fundamentals
- Price$3.12 as of 2026-07-09 close
- Market cap$513M as of 2026-07-10
- 1-year return+82.2% as of 2026-07-09 close
- ROE-131.6% as of 2026-07-10
- Debt / equity0.23 as of 2026-07-10
- Beta3.26 as of 2026-07-10
Key risks (from latest filing)
["Clinical and regulatory development risk: product candidates remain in late-stage clinical trials with uncertain outcomes; registrational trial for myositis initiated December 2025 with no guarantee of regulatory approval or commercial success"]
Competitors & peers
- Juno Therapeutics (JUNO / Celgene subsidiary)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.